Program
Digoxin
Also written as “digoxin”, “ZT002 injection, rosuvastatin, digoxin” and “Digoxin (0.25mg)”.
Its studies are mostly in Obesity · Neoplasms · Thalassemia · Carcinoma, Non-Small-Cell Lung · Liver Cirrhosis, led by 25 companies.
Drug pageDigoxin: every studyMany companies study it; this page follows only the 43 they lead. All 87 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheimits history only | 90 open or running | phase 1since Jun 1, 2010 | Jun 1, 2010 | none ahead |
| AstraZenecaits history only | 30 open or running | phase 1since Jul 8, 2008 | Jul 8, 2008 | none ahead |
| Bristol-Myers Squibbits history only | 30 open or running | phase 1since Oct 9, 2014 | Oct 9, 2014 | none ahead |
| Astellas Pharmaits history only | 20 open or running | phase 1since Apr 29, 2014 | Apr 29, 2014 | none ahead |
| GlaxoSmithKlineits history only | 20 open or running | phase 1since Mar 28, 2008 | Mar 28, 2008 | none ahead |
| Hoffmann-La Rocheits history only | 20 open or running | phase 1since Jan 9, 2013 | Jan 9, 2013 | none ahead |
| Johnson & Johnsonits history only | 20 open or running | phase 1since Jan 20, 2011 | Jan 20, 2011 | none ahead |
| Merckits history only | 20 open or running | phase 1since Aug 26, 2024 | Aug 26, 2024 | none ahead |
| Sanofiits history only | 20 open or running | phase 1since May 19, 2011 | May 19, 2011 | none ahead |
| AbbVieits history only | 10 open or running | phase 1since Feb 3, 2016 | Feb 3, 2016 | none ahead |
| Beijing QL Biopharmaceuticalits history only | 11 open or running | phase 1since Apr 20, 2026 | Apr 20, 2026 | Dec 5, 2026phase 1 · NCT07550816 |
| Biogenits history only | 10 open or running | phase 1since May 11, 2012 | May 11, 2012 | none ahead |
| CMP Developmentits history only | 10 open or running | phase 1since Feb 16, 2019 | Feb 16, 2019 | none ahead |
| CSLits history only | 10 open or running | phase 1since Nov 16, 2011 | Nov 16, 2011 | none ahead |
| Daiichi Sankyoits history only | 10 open or running | phase 1since Jan 4, 2012 | Jan 4, 2012 | none ahead |
| Eisaiits history only | 10 open or running | phase 1since Jan 23, 2014 | Jan 23, 2014 | none ahead |
| Eli Lillyits history only | 10 open or running | phase 1since Dec 16, 2023 | Dec 16, 2023 | none ahead |
| Jiangsu HengRui Medicineits history only | 10 open or running | phase 1since Mar 17, 2020 | Mar 17, 2020 | none ahead |
| Maruhoits history only | 10 open or running | phase 2since Dec 19, 2014 | Dec 19, 2014 | none ahead |
| Merck KGaA, Darmstadt, Germanyits history only | 10 open or running | phase 1since Sep 23, 2021 | Sep 23, 2021 | none ahead |
| Novo Nordiskits history only | 10 open or running | phase 1since Feb 3, 2025 | Feb 3, 2025 | none ahead |
| Pfizerits history only | 10 open or running | phase 1since Jan 27, 2009 | Jan 27, 2009 | none ahead |
| pharmaandits history only | 10 open or running | phase 1since Mar 30, 2016 | Mar 30, 2016 | none ahead |
| Puma Biotechnologyits history only | 10 open or running | phase 1since Mar 11, 2009 | Mar 11, 2009 | none ahead |
| Takedaits history only | 10 open or running | phase 1since Apr 20, 2016 | Apr 20, 2016 | none ahead |
Also a collaborator on its studies: Parexel, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene and Medpace.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 29 studies since Mar 28, 2008.
- Sep 17, 2019Phase 1 study in Prostatic NeoplasmsAstellas Pharma · NCT04094519 · 24 enrolled · Moldova, Republic of
- Jan 14, 2020Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT04231435 · 24 enrolled · United States
- Mar 17, 2020Jiangsu HengRui Medicine’s first study: phase 1 study in Advanced Solid TumorNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT04322552 · 18 enrolled · China
- Oct 15, 2020Phase 1 study in HealthyBoehringer Ingelheim · NCT04590937 · 15 enrolled · Germany
- Sep 23, 2021Merck KGaA, Darmstadt, Germany’s first study: phase 1 study in HealthyNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT05064488 · 40 enrolled · Germany
- Feb 14, 2023No phase study in Liver CirrhosisBoehringer Ingelheim · NCT05741372 · 28 enrolled · Germany
- Mar 3, 2023Phase 1 study in Healthy Male SubjectsAstraZeneca · NCT05768360 · 6 enrolled · Germany
- Dec 16, 2023Eli Lilly’s first study: phase 1 study in ObesityNew to Eli LillyEli Lilly · NCT06186622 · 50 enrolled · United States
- Aug 26, 2024Merck’s first study: phase 1 study in Carcinoma, Non-Small-Cell LungNew to MerckMerck · NCT06575933 · 28 enrolled · United States
- Oct 1, 2024Phase 1 study in HealthyMerck · NCT06625827 · 24 enrolled · United States
- Nov 5, 2024Phase 1 study in Healthy ParticipantsHoffmann-La Roche · NCT06677957 · 19 enrolled · United States
- Feb 3, 2025Novo Nordisk’s first study: phase 1 study in ThalassemiaNew to Novo NordiskNovo Nordisk · NCT06813924 · 37 enrolled · United States
- Aug 5, 2025Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT07118215 · 62 enrolled · United States
- Apr 20, 2026Beijing QL Biopharmaceutical’s first study: phase 1 study in OverweightNew to Beijing QL BiopharmaceuticalBeijing QL Biopharmaceutical · NCT07550816 · 60 enrolled · China
Ahead
- Dec 5, 2026Primary completion: phase 1 study in OverweightBeijing QL Biopharmaceutical · NCT07550816
TargetBeta
“Sodium/potassium-transporting ATPase inhibitor”ChEMBL 37, by rule
Other programs on the same 8 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Istaroximerule | windtree-therapeutics | phase 3 | 8 |
Studies
All 43 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07550816Overweight · China | 1 | Active, not recruiting | Beijing QL Biopharmaceutical | Dec 5, 2026 | 60 |
| NCT07118215Healthy Volunteers · United States | 1 | Completed | Bristol-Myers Squibb | Jun 25, 2026 | 62 |
| NCT06813924Thalassemia · United States | 1 | Completed | Novo Nordisk | May 27, 2025 | 37 |
| NCT06677957Healthy Participants · United States | 1 | Completed | Hoffmann-La Roche | Dec 30, 2024 | 19 |
| NCT06625827Healthy · United States | 1 | Completed | Merck | Jan 22, 2024 | 24 |
| NCT06575933Carcinoma, Non-Small-Cell Lung · United States | 1 | Completed | Merck | Oct 28, 2024 | 28 |
| NCT06186622Obesity · United States | 1 | Completed | Eli Lilly | Jul 10, 2024 | 50 |
| NCT05768360Healthy Male Subjects · Germany | 1 | Completed | AstraZeneca | Jun 24, 2023 | 6 |
| NCT05741372Liver Cirrhosis · Germany | – | Completed | Boehringer Ingelheim | Dec 18, 2024 | 28 |
| NCT05064488Healthy · Germany | 1 | Completed | Merck KGaA, Darmstadt, Germany | Dec 10, 2021 | 40 |
| NCT04590937Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jan 11, 2021 | 15 |
| NCT04322552Advanced Solid Tumor · China | 1 | Completed | Jiangsu HengRui Medicine | Apr 3, 2021 | 18 |
| NCT04231435Healthy Volunteers · United States | 1 | Completed | Bristol-Myers Squibb | Feb 19, 2020 | 24 |
| NCT04094519Prostatic Neoplasms · Moldova, Republic of | 1 | Completed | Astellas Pharma | Dec 27, 2020 | 24 |
| NCT03909529Drug Drug Interaction · India | 1 | Completed | CMP Development | Apr 19, 2019 | 28 |
| NCT03307252Healthy · Germany | 1 | Completed | Boehringer Ingelheim | May 2, 2018 | 45 |
| NCT02854527Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Nov 11, 2016 | 30 |
| NCT02775240Cytomegalovirus (CMV) · United States | 1 | Completed | Takeda | Sep 12, 2016 | 18 |
| NCT02740712Neoplasms · Poland | 1 | Completed | pharmaand | Mar 2017 | 17 |
| NCT02685462Healthy · United States | 1 | Completed | AbbVie | Feb 23, 2016 | 36 |
| NCT02345304Healthy · Germany | 1 | Withdrawn | Boehringer Ingelheim | Apr 2015 | 0 |
| NCT02333643Cutaneous Warts · Netherlands | 2 | Completed | Maruho | Aug 2015 | 81 |
| NCT02262520N/A - Healthy Subjects | 1 | Completed | Bristol-Myers Squibb | Mar 2006 | 24 |
| NCT02231931Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jan 1, 2015 | 24 |
| NCT02171052Healthy | 1 | Completed | Boehringer Ingelheim | Aug 2006 | 24 |
| NCT02127034Healthy Subjects · Germany | 1 | Completed | Astellas Pharma | Jun 2014 | 26 |
| NCT02055703Healthy Subjects · United States | 1 | Completed | Eisai | Apr 2014 | 195 |
| NCT01765569Melanoma · Belarus, Israel, Korea, Republic of and more | 1 | Completed | Hoffmann-La Roche | Jun 2014 | 29 |
| NCT01598363Healthy Volunteers · United States | 1 | Completed | Biogen | Jul 31, 2012 | 32 |
| NCT01561781Healthy Volunteers · United States | 1 | Completed | Sanofi | Jul 2012 | 14 |
| NCT01583036Epilepsy · United States | 1 | Completed | GlaxoSmithKline | Apr 17, 2012 | 30 |
| NCT01517399Neoplasms · United States | 1 | Completed | Daiichi Sankyo | Aug 2013 | 28 |
| NCT01519128Acquired Immunodeficiency Syndrome · Belgium | 1 | Completed | Johnson & Johnson | Apr 2012 | 22 |
| NCT01477411Drug Interaction Potentiation · United States | 1 | Completed | CSL | Jan 2012 | 42 |
| NCT01357811Healthy Volunteer · United States | 1 | Completed | Sanofi | Nov 2011 | 28 |
| NCT01306175Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Apr 2011 | 20 |
| NCT01288742Hepatitis C | 1 | Completed | Johnson & Johnson | May 2011 | 33 |
| NCT01134965Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jul 2010 | 24 |
| NCT00904176Diabetes Mellitus, Type 2 · United States | 1 | Completed | AstraZeneca | Aug 2009 | 30 |
| NCT00860223Healthy · United States | 1 | Completed | Puma Biotechnology | Apr 2009 | 27 |
| NCT00831506Alzheimer Disease · United States | 1 | Completed | Pfizer | May 2009 | 12 |
| NCT00712465Atrial Fibrillation · Sweden | 1 | Completed | AstraZeneca | Nov 2008 | 18 |
| NCT00650910Breast Neoplasms · United States, Canada, Korea, Republic of | 1 | Completed | GlaxoSmithKline | Jul 10, 2009 | 17 |
How it is read
Names in the registry
- “Digoxin”, 33 entries
- “digoxin”, 6 entries
- “ZT002 injection, rosuvastatin, digoxin”, 1 entry
- “Digoxin (0.25mg)”, 1 entry
- “Lenoxin®”, 1 entry
Conditions, from the studies’ own filings
- Obesity, 2 studies
- Neoplasms, 2 studies
- Thalassemia, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Liver Cirrhosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.